The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will "urgently accelerate development" of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo.
Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate. The funding will simultaneously allow the company to ramp up manufacturing capabilities and ready large-scale Phase 2/3 trials in the event the vaccine makes it through early testing. The vaccine will use Moderna's mRNA vaccine platform that allowed for rapid development of a COVID-19 vaccine during the pandemic.
"[W]e believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," Moderna CEO Stéphane Bancel said in a statement Monday. " We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will "urgently accelerate development" of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo.
Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate. The funding will simultaneously allow the company to ramp up manufacturing capabilities and ready large-scale Phase 2/3 trials in the event the vaccine makes it through early testing. The vaccine will use Moderna's mRNA vaccine platform that allowed for rapid development of a COVID-19 vaccine during the pandemic.
"[W]e believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," Moderna CEO Stéphane Bancel said in a statement Monday. " We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
Nvidia's announcement that it's getting into the consumer laptop chip space with RTX Spark is huge. Apple has proved for years that Arm-based chips can perform incredibly well while also delivering great battery life - at least on the Mac. In the Windows world, performance hasn't fully matched up under Qualcomm chips, mostly in the graphics department. There's clearly still untapped potential, and Nvidia seems to be promising to deliver it.
This could be Windows' moment to blow us away with a new generation of supremely capable chips, much like Apple's back in 2020, with the introduction of the M1. But why does this launch feel simultaneous …
Surging memory costs are pushing action-camera maker GoPro Inc. to the brink. The company, founded by Nicholas Woodman, warned of risks to its ability to continue as a going concern and is seeking financing to avert a default, according to a latest filing.
Miguel S. Albergaria dá continuidade aos seus artigos sobre a Ética na IA e escreve sobre o seu processo, ou sobre conceber a inteligência que estes artefactos implementam.
Depois daquela que foi considerada a mais relevante apresentação, até agora, na Computex 2026, está na altura de conhecer um pouco melhor o que é o Nvidia RTX Spark, e quais os primeiros equipamentos a virem equipados com o mesmo.
The artificial intelligence company, which is racing OpenAI to the stock market, has seen explosive growth over the last year thanks largely to technology that can automatically write computer code.
Com o prazo das candidaturas para o Cheque Formação+Digital a terminar, reunimos uma seleção com 6 cursos de curta duração que ainda podem ser concluídos a tempo de beneficiar do apoio.